Abstract
Gastroesophageal reflux disease (GERD) is a common non-respiratory comorbidity in patients with non-tuberculous mycobacterial pulmonary disease (NTM-PD). However, little is known about the association between GERD and healthcare utilization and medical costs of NTM-PD. Thus, we evaluated this association using the Health Insurance Review and Assessment Service National Patient Sample. NTM-PD patients with GERD had significantly higher healthcare use and spent a higher total on medical costs (5,098 vs. 2,675 USD/person/year) than those without GERD (P <0.001 for all). Therefore, an appropriate management of GERD in NTM-PD patients can be an important factor to reduce the disease burden.
Introduction
The prevalence and incidence of non-tuberculous mycobacterial pulmonary disease (NTM-PD) has been increasing worldwide (1). Furthermore, both the attributable mortality and financial burden associated with this disease are high (2). Thus, clinical studies that identify preventable or treatable factors to address the high disease burden of NTM-PD are urgently needed to determine strategies for reducing the burden. Gastroesophageal reflux disease (GERD) is a common non-respiratory comorbidity in NTM-PD patients, with a prevalence of 26–44% (3, 4). GERD is associated with an increased number of aspiration symptoms, higher bacterial burden, and more severe radiologic findings (3, 4). Although these results indicate that the disease burden in NTM-PD patients with GERD can be more substantial than in those without GERD, there is limited information on this issue. Thus, we aimed to evaluate whether GERD is associated with a higher disease burden, specifically healthcare use, medical costs, and in-hospital mortality, in patients with NTM-PD.
Methods
Data Source
We used the 2009–2017 Health Insurance Review and Assessment Service, National Patient Sample (HIRA-NPS), which includes ~1,400,000 individuals each year drawn by 3% stratified random sampling by age and sex from the entire population with claims records during the year. The dataset included patient diagnosis, treatment, procedures, surgical history, and prescription drugs. Diagnosis was coded according to the 10th edition of the International Classification of Diseases (ICD-10). Generic drugs were coded according to the Korean National Code System (5).
Study Population
NTM-PD was defined by ICD-10 diagnosis codes of A31.0, A31.8, and A31.9; GERD was defined by ≥2 claims under the ICD-10 code K21 and proton pump inhibitors prescribed for ≥2 weeks (6). We included 6,589 patients with NTM-PD from January 2009 to December 2017 using the ICD-10 code, of which 1,407 patients had GERD. The Institutional Review Board of Chungbuk National University Hospital approved the study and waived the requirement for informed consent because the HIRA-NPS data were deidentified (application no. CBNUH 2021-03-020).
Outcomes
Respiratory-related healthcare use was defined as healthcare use under the ICD-10 codes of respiratory diseases (J00–J99). We compared healthcare use (outpatient department [OPD] visits, emergency room [ER] visits, or hospitalizations), medical costs, and in-hospital mortality in NTM-PD patients with GERD to those in patients without GERD. The medical cost consists of expenses related to diagnostic tests, procedures, and treatments covered by the National Health Insurance (7).
Covariables
Comorbidities were also defined using ICD-10 codes. Pulmonary comorbidities were defined as chronic obstructive pulmonary disease (COPD; J42–J44, except J43.0 [unilateral emphysema]), asthma (J45–J46), bronchiectasis (J47, excluding E84 [cystic fibrosis] or Q33.4, Q89.3 [congenital bronchiectasis]), pulmonary tuberculosis (TB; A15–19), and lung cancer (C33–C34). Extrapulmonary comorbidities were defined as cerebrovascular disease (G45–G46, I60–I69, and H34.0), hypertension (I10–I15), angina or myocardial infarction (MI; I20, I21, I22, and I25.2), congestive heart failure (I43, I50, I09.9, I11.0, I25.5, I13.0, I13.2, I42.0, I42.5–I42.9, and P29.0), inflammatory bowel disease (K50–K51), diabetes mellitus (E10–E14), chronic kidney disease (N18), and connective tissue disease (M05, M06, M315, M32, M33, M34, M351, M353, and M360) (5, 8). The Charlson comorbidity index (CCI) was calculated using a modified version consisting of 17 comorbidities (9).
Statistical Analysis
We calculated the age-adjusted prevalence of GERD among patients with NTM-PD by dividing the number of events by 1,000 person-years. All categorized variables were compared using Pearson's chi-squared test. To compare the medical use of NTM-PD patients with and without GERD, logistic regression analysis was used to determine the odds ratio (OR) for healthcare use (ER visits or hospitalizations) and in-hospital mortality in NTM-PD patients with GERD relative to those without GERD. A multivariable model was adjusted for age, sex, type of insurance (health insurance, medical aid, and veteran status), bronchiectasis, and CCI (0–1 and ≥2). All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was set at P < 0.05.
Results
Baseline Characteristics
The baseline characteristics of the patients are summarized in Table 1. The prevalence of NTM-PD in patients with GERD was significantly higher in older age groups (≥60 years [60.4 vs. 42.8%], P < 0.001). However, there was no difference in the sex ratio (~62% of the cases were female). The proportion of patients who received medical aid was higher in the NTM-PD with GERD group than in those without GERD (7.3 vs. 3.8%, P < 0.001). Analysis of comorbidities indicated that the rates of asthma (40.9 vs. 25.7%), chronic obstructive pulmonary disease (37.5 vs. 23.0%), bronchiectasis (28.9 vs. 24.1%), hypertension (44.1 vs. 27.6%), diabetes mellitus (34.0 vs. 19.0%), cerebrovascular disease (15.7 vs. 7.8%), connective tissue disease (12.3 vs. 4.5%), and CCI ≥ 2 (78.2 vs. 49.0%) were significantly higher in NTM-PD patients with GERD than in those without GERD (P < 0.001 for all).
Table 1
| Total (N = 6,589) | NTM-PD with GERD (n = 1,407) | NTM-PD without GERD (n = 5,182) | P-value | |
|---|---|---|---|---|
| Age, years | <0.001 | |||
| 20–29 | 499 (7.6) | 25 (1.8) | 474 (9.2) | |
| 30–39 | 877 (13.3) | 96 (6.8) | 781 (15.1) | |
| 40–49 | 789 (12.0) | 125 (8.9) | 664 (12.8) | |
| 50–59 | 1,360 (20.5) | 311 (22.1) | 1,049 (20.1) | |
| 60–69 | 1,407 (21.4) | 403 (28.6) | 1,004 (19.4) | |
| ≥70 | 1,657 (25.2) | 447 (31.8) | 1,210 (23.4) | |
| Sex | 0.614 | |||
| Male | 2,458 (37.3) | 533 (37.9) | 1,925 (37.2) | |
| Female | 4,131 (62.7) | 874 (62.1) | 3,257 (62.8) | |
| Type of insurance | <0.001 | |||
| Health insurance | 6,283 (95.3) | 1,302 (92.5) | 4,981 (96.2) | |
| Medical aid | 301 (4.6) | 102 (7.3) | 199 (3.8) | |
| Veteran status | 5 (0.1) | 3 (0.2) | 2 (0.0) | |
| Comorbidities | ||||
| COPD | 1,720 (26.1) | 528 (37.5) | 1,192 (23.0) | <0.001 |
| Asthma | 1,909 (29.0) | 575 (40.9) | 1,334 (25.7) | <0.001 |
| Bronchiectasis | 1,653 (25.1) | 406 (28.9) | 1,247 (24.1) | <0.001 |
| Cerebrovascular disease | 626 (9.5) | 221 (15.7) | 405 (7.8) | <0.001 |
| Hypertension | 2,051 (31.1) | 620 (44.1) | 1,431 (27.6) | <0.001 |
| Diabetes mellitus | 1,464 (22.2) | 478 (34.0) | 986 (19.0) | <0.001 |
| Connective tissue disease | 405 (6.2) | 173 (12.3) | 232 (4.5) | <0.001 |
| Charlson comorbidity index | <0.001 | |||
| 0–1 | 2,952 (44.8) | 307 (21.8) | 2,645 (51.0) | |
| ≥2 | 3,637 (55.2) | 1,100 (78.2) | 2,537 (49.0) |
Characteristics of study population.
Data are presented as numbers (percentages).
NTM-PD, non-tuberculous mycobacterial pulmonary disease; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease.
Prevalence of GERD in Patients With NTM-PD
Of the 6,589 patients with NTM-PD, 1,407 had GERD. During the study period, the prevalence of GERD in patients with NTM-PD was 21.4%, which was higher than that in patients aged ≥20 years (7.4%) in the HIRA-NPS database. The prevalence of GERD in patients with NTM-PD increased with age.
Healthcare Use and Medical Costs According to the Presence or Absence of GERD
NTM-PD patients with GERD had significantly higher healthcare use, including all-cause and respiratory disease-specific OPD visits and ER visits or hospitalizations, than those without GERD (P < 0.001 for all). Furthermore, NTM-PD patients with GERD spent a higher total on medical costs (5,098 vs. 2,675 USD/person/year), including respiratory disease-related costs (1,230 vs. 491 USD/person/year) (P < 0.001 for both) (Figure 1).
Figure 1
Association Between GERD and Increased Healthcare Use
GERD was independently associated with more ER visits or hospitalizations in patients with NTM-PD: all-cause (adjusted OR, 1.45; 95% confidence interval [CI], 1.27–1.64) and respiratory disease-related (adjusted OR, 1.26; 95% CI, 1.07–1.48). However, GERD was not significantly associated with in-hospital mortality (adjusted OR 1.11, 95% CI, 0.76–1.61) (Figure 2).
Figure 2
Discussion
To our knowledge, this study is the first to evaluate the impact of GERD on the estimated disease burden based on healthcare use, medical costs, and in-hospital mortality in patients with NTM-PD. NTM-PD patients with GERD had significantly higher healthcare use and medical costs than those without GERD; however, there were no significant intergroup differences in in-hospital mortality.
GERD is prevalent in patients with NTM-PD, affecting up to 44% of patients (3, 4). In agreement with previous reports, 21% of patients with NTM-PD had GERD, which was significantly higher than the prevalence of GERD (7%) in the overall population aged ≥20 years during the study period. GERD has been recognized not only as an underlying disease for the occurrence of NTM-PD (10) but also as an important comorbidity that can influence the symptoms and severity of the disease (3, 10). In this regard, this study revealed NTM-PD patients with GERD are hampered by greater healthcare use and higher medical costs, which denote a significant disease burden, compared to those without GERD.
Gastro-esophageal refluxate can aggravate respiratory disease by either stimulating the sensitized esophageal-bronchial neuronal pathway or by microaspiration, which involves aspiration into the airway (11). Conversely, it has been suggested that progression of chronic lung disease can lead to deterioration of GERD (12). Consequently, it can be postulated that the interaction between the two diseases may further deteriorate the health of patients with NTM-PD and GERD. Considering the potential bidirectional process between reflux disease and chronic respiratory disease (13), appropriate treatment of GERD may lead to decreased disease burden and improvement in overall treatment outcomes in patients with NTM-PD. However, since acid reduction cannot reduce refluxate other than acid, there is a possibility that non-acid refluxate can still cause lung damage. Thus, it should be acknowledged that it is challenging to reduce reflux itself.
Our study has several strengths that support our hypothesis and was based on a large, nationally representative database. However, there are some limitations to this study. First, we used a cross-sectional study design; thus, long-term mortality was not fully evaluated based on the presence or absence of GERD. Second, there is a possibility of misclassification because we used the ICD-10 codes to define NTM-PD and GERD. Therefore, a large prospective cohort study is needed to clarify the role of GERD in NTM-PD.
In conclusion, GERD significantly increased healthcare use and medical costs in patients with NTM-PD. Thus, appropriate diagnostic and management plans to reduce the GERD-associated disease burden would bring significant improvements to patients with NTM-PD.
Funding
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, Information, and Communications Technologies (Nos. 2020R1F1A1070468 and 2021M3E5D1A0101517621 to HL) and the Korean Ministry of Education (No. 2021R1I1A3052416 to HC). The funders had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found here: https://opendata.hira.or.kr/op/opc/selectPatDataAplInfoView.do.
Author contributions
HL and HC were responsible for the conception and design of the study. TK, JHY, BY, JR, CKY, YK, JWS, HL, and HC undertook the analysis and interpretation of the data. TK, JHY, BY, HL, and HC drafted the manuscript. All authors made a critical revision of the manuscript, and read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
PrevotsDRMarrasTK. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria: a review. Clin Chest Med. (2015) 36:13–34. 10.1016/j.ccm.2014.10.002
2.
DielRJacobJLampeniusNLoebingerMNienhausARabeKFet al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. (2017) 49:2016. 10.1183/13993003.02109-2016
3.
KohWJLeeJHKwonYSLeeKSSuhGYChungMPet al. Prevalence of gastroesophageal reflux disease in patients with non-tuberculous mycobacterial lung disease. Chest. (2007) 131:1825–30. 10.1378/chest.06-2280
4.
ThomsonRMArmstrongJGLookeDF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest. (2007) 131:1166–72. 10.1378/chest.06-1906
5.
ChoiHYangBNamHKyoungDSSimYSParkHYet al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J. (2019) 54:1900194. 10.1183/13993003.00194-2019
6.
KimSYMinCOhDJChoiHG. Bidirectional association between GERD and asthma: two longitudinal follow-up studies using a national sample cohort. J Allergy Clin Immunol Pract. (2020) 8:1005–13. 10.1016/j.jaip.2019.10.043
7.
KimJAYoonSKimLYKimDS. Towards Actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. (2017) 32:718–28. 10.3346/jkms.2017.32.5.718
8.
ChoiHHanKYangBShinDWSohnJWLeeH. Female reproductive factors and incidence of non-tuberculous mycobacterial pulmonary disease among postmenopausal women in Korea. Clin Infect Dis. (2022). 10.1093/cid/ciac134
9.
BrusselaersNLagergrenJ. The charlson comorbidity index in registry-based research. Methods Inf Med. (2017) 56:401–6. 10.3414/ME17-01-0051
10.
GriffithDEGirardWMWallace RJJr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria An analysis of 154 patients. Am Rev Respir Dis. (1993) 147:1271–8. 10.1164/ajrccm/147.5.1271
11.
HoughtonLALeeASBadriHDeVaultKRSmithJA. Respiratory disease and the oesophagus: reflux, reflexes, and microaspiration. Nat Rev Gastroenterol Hepatol. (2016) 13:445–60. 10.1038/nrgastro.2016.91
12.
MoreheadRS. Gastro-oesophageal reflux disease and non-asthma lung disease. Eur Respir Rev. (2009) 18:233–43. 10.1183/09059180.00002509
13.
McDonnellMJHuntEBWardCPearsonJPO'TooleDLaffeyJGet al. Current therapies for gastro-esophageal reflux in the setting of chronic lung disease: state of the art review. ERJ Open Res. (2020) 6:190. 10.1183/23120541.00190-2019
Summary
Keywords
NTM, non-tuberculous mycobacteria, GERD (gastroesophageal reflux disease), population base study, medical cost, disease burden
Citation
Kim T, Yoon JH, Yang B, Ryu J, Yoon CK, Kim Y, Sohn JW, Lee H and Choi H (2022) Healthcare Utilization and Medical Cost of Gastrointestinal Reflux Disease in Non-tuberculous Mycobacterial Pulmonary Disease: A Population-Based Study, South Korea, 2009–2017. Front. Med. 9:793453. doi: 10.3389/fmed.2022.793453
Received
12 October 2021
Accepted
21 March 2022
Published
18 April 2022
Volume
9 - 2022
Edited by
Laurent Pierre Nicod, University of Lausanne, Switzerland
Reviewed by
Fernando A. M. Herbella, Federal University of São Paulo, Brazil; David Griffith, National Jewish Health, United States
Updates
Copyright
© 2022 Kim, Yoon, Yang, Ryu, Yoon, Kim, Sohn, Lee and Choi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hyun Lee namuhanayeyo@hanynang.ac.krHayoung Choi hychoimd@gmail.com
†These authors have contributed equally to this work
This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.